advertisement
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (12)
Showing records 1 to 12
Search within classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation50556 Tear Film Osmolarity in Patients Treated for Glaucoma or Ocular Hypertension
Labbé A; Terry O; Brasnu E; Van Went C; Baudouin C
Cornea 2012; 31: 994-999
50614 Stem cell-based delivery of brain-derived neurotrophic factor gene in the rat retina
Park HY; Kim JH; Sun Kim H; Park CK
Brain Research 2012; 1469: 10-23
50462 Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
Ermiş SS
Clinical Ophthalmology 2012; 6: 673-678
50570 Extended drug delivery by contact lenses for glaucoma therapy
Peng CC; Burke MT; Carbia BE; Plummer C; Chauhan A
Journal of Controlled Release 2012; 162: 152-158
50468 Determination of permeability coefficients of ophthalmic drugs through different layers of porcine, rabbit and bovine eyes
Loch C; Zakelj S; Kristl A; Nagel S; Guthoff R; Weitschies W; Seidlitz A
European Journal of Pharmaceutical Sciences 2012; 47: 131-138
50376 Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: Development, characterization and in vitro evaluation of their antitumoral efficacy
Herná,n Pé,rez de la Ossa D; Ligresti A; Gil-Alegre ME; Aberturas MR; Molpeceres J; Di Marzo V; Torres Suá,rez AI
Journal of Controlled Release 2012; 161: 927-932
50490 A Comparative Study of a Preservative-Free Latanoprost Cationic Emulsion (Catioprost(®)) and a BAK-Preserved Latanoprost Solution in Animal Models
Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
Journal of Ocular Pharmacology and Therapeutics 2012; 28: 515-523
50536 A comparison of 0.1% timolol eye gel and 0.5% timolol eye drop in patients with chronic angle-closure glaucoma
Metheetrairut A; Leumsamran P; Rojananin S; Kitnarong N
Journal of the Medical Association of Thailand 2012; 95: S116-122
50214 Single and mixed poloxamine micelles as nanocarriers for solubilization and sustained release of ethoxzolamide for topical glaucoma therapy
Ribeiro A; Sosnik A; Chiappetta DA; Veiga F; Concheiro A; Alvarez-Lorenzo C
Journal of the Royal Society, Interface / the Royal Society 2012; 9: 2059-2069
50525 Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients
Rossi GC; Pasinetti GM; Raimondi M; Ricciardelli G; Scudeller L; Blini M; Amisano A; Bianchi PE
Expert Opinion on Drug Safety 2012; 11: 519-525
50583 Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension
Baudouin C; Renard JP; Nordmann JP; Denis P; Lachkar Y; Sellem E; Rouland JF; Jeanbat V; Boué,e S
European Journal of Ophthalmology 2012; 0: 0
50527 Benzalkonium chloride breaks down conjunctival immunological tolerance in a murine model
Galletti JG; Gabelloni ML; Morande PE; Sabbione F; Vermeulen ME; Trevani AS; Giordano MN
Mucosal immunology 2013; 6: 24-34
